Implant Market: Growing, But Consolidating

Eighteen implants a year looks like a $39,600 service line. Put a value on the chair time it eats and it nets you about $380 less than leaving those hours to hygiene, crowns and recall. That is the uncomfortable arithmetic sitting underneath the fastest-growing surgical procedure in general dentistry, and almost nobody running it part-time has done the sum.

Here is our call, and it will annoy a lot of good clinicians: implants have become a volume business, and the independent owner placing fewer than three a month should either commit to tripling that number inside twelve months or stop placing and keep the restorative half of the case. The mushy middle, one or two a month, is the worst position in a market where demand is climbing and the people who sell you parts are getting fewer and larger.

Demand Is Up 738%, and the Vendor List Keeps Getting Shorter

The clinical trend is not in question. Among U.S. adults with missing teeth, implant prevalence went from 0.7% in 1999-2000 to 5.7% in 2015-2016, a 738% relative increase, averaging a covariate-adjusted 14% rise per year (95% CI 11% to 18%). The same analysis put 2026 somewhere between 5.7% (if the trend simply stopped) and 23% (if it accelerated). Even the pessimistic end of that range means a procedure that was rare when most practice owners finished school is now a standing line item in treatment planning.

Now look at who sells you the hardware. On February 9, 2026, Nobel Biocare, part of Envista Holdings, announced its acquisition of Versah, the company behind the patented Densah Bur and osseodensification site preparation. That is not a small tuck-in. It is a top-tier manufacturer buying the technique layer that sits between your drill and your fixture. A market research summary of the 2024-2029 implant forecast names Straumann, Dentsply Sirona, Zimmer Biomet, Henry Schein, Envista, Dentium and Osstem Implant as the set of vendors driving share. Seven names, and two of them have been buying.

Growing demand plus a consolidating supply side is a good setup if you buy in volume and a bad one if you buy in ones and twos. Nobody at a manufacturer is losing sleep over the account that orders 18 fixtures a year.

Eighteen Implants a Year Is a Break-Even Hobby

Run two practices side by side. Same fee, same clinician, different volume. Assume a surgical placement fee of $2,200, a practice-wide production rate of $650 per clinical hour, and $6,500 a year in fixed platform cost (surgical kit replacement and refurbishment, planning software subscription, implant CE). These are illustrative numbers; swap in your own and the shape does not change.

Practice A places 18 a year. It buys at or near list: $560 per case for fixture, healing abutment, final abutment and impression components. Revenue is 18 times $2,200, or $39,600. Components run 18 times $560, or $10,080. Subtract the $6,500 fixed platform cost and contribution is $23,020. Now the part owners skip. At low volume each case burns about two clinical hours once you count the extended consult, the longer surgical appointment and the unbillable callback, so 18 cases take 36 hours. Those 36 hours would otherwise produce 36 times $650, or $23,400. Net against the alternative use of the chair: minus $380.

Practice B places 60 a year. Five a month earns a real volume tier, so components land at $380 per case, and reps and sequence efficiency bring surgical time down to 1.5 hours. Revenue is 60 times $2,200, or $132,000. Components are 60 times $380, or $22,800. Same $6,500 fixed cost, so contribution is $102,700. Chair time is 90 hours, worth $58,500 at the house rate. Net gain over the alternative: $44,200, or $737 per implant placed.

Three things drove that gap, and only one of them is clinical. Component pricing improved by $180 a case. Surgical time dropped by half an hour. And the $6,500 fixed cost spread across 60 cases instead of 18, falling from $361 per case to $108. Volume is not bragging. It is the entire margin.

Eighteen implants a year isn't a service line, it's an expensive hobby with a torque wrench.

What Most Owners Get Wrong: Counting the Fee, Not the Chair

The specific mistake: treating the implant fee as margin because the component cost is small relative to it. We see it most often in GPs five to fifteen years out who took a weekend surgical course, bought the kit, and now place a handful of cases a year because the course was good and the first few healed. The fee looks enormous next to a $560 parts invoice, so the case feels like the most profitable thing on the schedule. It isn't, because the comparison is wrong. The question is never "did this case make money," it's "did this case out-earn whatever else that operatory would have done in the same hours."

The second version of the mistake is the fixed cost. A surgical kit, a guided planning subscription and a CE habit are the same price whether you place 18 or 80. Owners expense them once, forget them, and never allocate them per case. At 18 cases that is $361 of real cost per implant that nobody writes down.

Our view: the write-down nobody makes is the most expensive one. If your implant line can't clear your hourly production rate after fixed costs, you are subsidizing a skill you enjoy with money from hygiene.

Why DSO Affiliation Shows Up on Your Purchase Order

Consolidation is happening on both sides of the invoice at once. ADA Health Policy Institute found that in 2024, more than 1 in 4 U.S. dentists up to 10 years out of dental school were affiliated with a DSO, a higher share than any prior cohort, based on an analysis of roughly 200,000 practicing dentists. Those are the clinicians placing most of the implants in the next two decades, and they will mostly be buying through a group contract that commits to annual unit volume.

So picture the sales side of a manufacturer that just spent money buying a technique company. It has a finite number of reps and a narrowing field of competitors. It can sign one agreement covering 400 clinicians, or it can court 400 solo accounts ordering a dozen fixtures each. Nothing about that choice is hostile to independents. It is simply where the attention goes, and attention is what sets your component price, your rep response time and whether you get the training slot.

That is the real squeeze. Not that implant demand will go elsewhere, but that the per-unit cost of serving it will stop falling for small buyers while it keeps falling for large ones. The Versah deal is a preview: when the site-preparation technique sits inside the fixture company, the bundle gets priced for people who buy bundles.

If You're Buying, Don't Pay for Someone Else's Implant Line

This matters on acquisition too. The Dental Signal Practice Market Index, built from dental practice broker listings, shows the practices currently on the market cluster tightly: median collections of $957,588 with the middle half between $650,000 and $1,500,000 (n=753), a median of 5 operatories (n=754), and median collections per operatory of $200,000 (n=643). These describe the asking side of the market, not practices generally, but they tell you what a listed practice looks like: five chairs, roughly two hundred thousand a chair, and no spare room.

When a listing or a seller pitches "we do implants here," apply the three-a-month test before you value it at a dollar. Ask for 24 months of placement counts by provider, the component spend, and whether the seller's volume tier transfers. Usually you'll find a line that produced 15 to 25 cases a year with a clinician who is leaving. That is not a service line you are buying, it is a kit in a cupboard and a surgical course you will have to pay for yourself. We wouldn't pay a premium for it.

The flip side is genuinely valuable: a practice doing 60-plus placements a year with a documented referral pattern and a transferable contract is a different asset, and it is worth asking why it's for sale.

Pick Your Lane Before the Next Kit Invoice

Pull your last 24 months of implant placements and divide by 24 to get your real monthly rate, then multiply your fixed platform spend by nothing you hope for and divide it by that actual count. If you're under three a month, decide this week which way you're going: book a surgical block, set a referral-marketing number and commit to 36 placements over the next twelve months, or stop placing, build a formal restorative arrangement with a surgeon, and keep the abutment-and-crown half at full fee with none of the surgical risk. Then call your rep and ask, in writing, what unit volume gets you the next price tier and what happens to that tier if you hit it. If the answer is vague, you're a list-price account and you should price your cases that way.

We're watching two things from here. First, whether Envista prices osseodensification as a standalone technique or folds it into platform purchasing, because that tells you how tight the bundling gets across the other six major vendors. Second, whether third-party components and open-architecture planning keep holding quality at the low end. If small buyers can assemble a reliable case at group-contract cost without a group contract, the three-a-month threshold drops and we'll say so. Until then, volume is the only thing standing between your implant line and your hygiene schedule subsidizing it.

If you want to see where your implant line actually lands once fixed platform cost and chair time are allocated against it, benchmark your own numbers: our free overhead calculator lets you set your per-operatory cost and clinical hourly rate, so you can test whether a part-time surgical line is clearing it or quietly dragging it down. Run your own numbers before you sign the next kit invoice.